HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks
Author:
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Oncology
Reference89 articles.
1. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways
2. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells
3. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
4. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Exploring Therapeutic Challenges in Patients with HER2-Positive Breast Cancer—A Single-Center Experience;Life;2024-08-18
2. Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers;International Journal of Molecular Sciences;2024-01-15
3. Role of the Tumor Microenvironment in Mediating Resistance to Anti-HER2 Antibodies;Critical Reviews™ in Oncogenesis;2024
4. Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer;Frontiers in Oncology;2023-08-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3